RNAZ: TransCode Earnings growth forecast for next year
TransCode Therapeutics attracts leading geneticists through high R&D funding and comprehensive benefits packages. The projected EPS trend for the company for the coming year demonstrates market expectations, where the 0.00 mark reflects the latest data. Growth is driven by the TTX platform's magnetic nanoparticles, while stock options and ambitious oncology research programs ensure the retention of bioinformaticians.
TransCode Therapeutics, Inc. - analytical breakdowns and key metrics (RNAZ)
- share price and consensus valuation forecast:
- market capitalization information:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Capital TransCode Therapeutics|RNAZ - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital TransCode Therapeutics Inc.|RNAZ - Company Cumulative Debt|Debt to Book Capitalization Ratio TransCode Therapeutics|RNAZ - Company Long-Term Loans and Borrowings|Company Short-Term Debts TransCode Therapeutics|Quick Liquidity transcodetherapeutics.com
- earnings and market ratios statistics:
RNAZ - Profit After Tax|Projected Future Earnings TransCode Therapeutics|RNAZ - Market Cap to Earnings|Projected Price to Earnings TransCode Therapeutics Inc.|RNAZ - PEG Multiple|Enterprise Value to EBITDA Ratio TransCode Therapeutics|RNAZ - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) TransCode Therapeutics|RNAZ - Net earnings per share for the last four quarters|Quarterly EPS earnings growth transcodetherapeutics.com|RNAZ - Net earnings per share growth this year|Net earnings per share growth forecast for next year TransCode Therapeutics
Fundamental company analysis:RNAZ, TransCode Therapeutics
For TransCode Therapeutics (RNAZ), which operates in the underserved segment of cancer RNA therapy, this metric reflects the potential to monetize R&D through partnerships with pharma behemoths. By analyzing expectations for changes in net income per share, an investor can track the daily price action of consensus EPS forecasts for the coming year, enabling an objective assessment of market optimism and the avoidance of excessive risks when purchasing the asset at a valuation peak.
Competitor analysis for TransCode Therapeutics
TEM (Tempus AI, Inc) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year QGEN (Qiagen Corp)|Earnings growth forecast for next year IONS|RGEN - Expected net earnings per share growth next year|Avidity Biosciences, Inc. - Expected earnings per share growth for next year|Expected earnings per share trend next year CRSP|WGS: Expected earnings per share growth for next year|Ultragenyx Corp - Projected earnings per share increase next year|BEAM: Earnings growth forecast for next year|sarepta.com - Expected earnings per share trend next year|TWST (Twist Bioscience, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year 10x Genomics Inc TXG|Net earnings per share growth forecast for next year Intellia (NTLA)|STOK (Stoke Corp) - Expected earnings per share trend next year|Earnings growth forecast for next year BLFS (BioLife Solutions, Inc.)|Earnings growth forecast for next year wavelifesciences.com WVE|MAZE - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year SION|PRME: Earnings growth forecast for next year|Expected net earnings per share growth next year Taysha Corp (TSHA)|Expected earnings per share growth for next year QURE|Earnings growth forecast for next year meiragtx.com|Expected earnings per share growth for next year RGNX (REGENXBIO)|Projected earnings per share increase next year SLDB|Earnings growth forecast for next year OCGN (Ocugen Corp)|Consensus forecast of earnings per share growth for next year PacBio Corp (PACB)|Benitec Biopharma Inc. - Earnings growth forecast for next year|designtx.com (DSGN) - Expected earnings per share growth for next year|Rocket Pharmaceuticals, Inc. (RCKT) - Net earnings per share growth forecast for next year|FDMT - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Lexeo Therapeutics Inc.|KRRO: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Editas Medicine, Inc. (EDIT)|silence-therapeutics.com - Projected earnings per share growth rate for next year|Earnings growth forecast for next year PRQR (ProQR Therapeutics)|Earnings growth forecast for next year Codexis Inc CDXS|SGMO: Expected earnings per share growth for next year|Net earnings per share change forecast for next year NAUT|MGX: Earnings growth forecast for next year|Projected earnings per share growth rate for next year DTIL|Net earnings per share growth forecast for next year Generation Bio Co|Projected earnings per share growth rate for next year BOLD (Boundless Bio Inc.)|Earnings growth forecast for next year XCUR|Earnings growth forecast for next year imunon.com (IMNN)|Phio Pharmaceuticals Corp. - Expected earnings per share growth for next year|Projected earnings per share increase next year MBIO (Mustang Bio Inc)|BNGO - Net earnings per share growth forecast for next year|Expected earnings per share trend next year APDN (Applied DNA Sciences Inc)|BLUE: Earnings growth forecast for next year|ImmunoPrecise Antibodies Ltd. (IPA) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Omega Therapeutics|Projected earnings per share growth rate for next year OMIC (singulargenomics.com)|Net earnings per share growth forecast for next year Regulus Therapeutics Inc. (RGLS)|Consensus forecast of earnings per share growth for next year Syros Pharmaceuticals Inc.|Earnings growth forecast for next year TBIO (Codex DNA)|TCON - Expected earnings per share growth for next year|UBX - Net earnings per share growth forecast for next year
